

Pressure BioSciences, Inc.

12:52 09 Jan 2020

Pressure BioSciences's PCT platform featured in more than 20 scientific articles for second year in a row

Pressure BioSciences Inc (OTCMKTS:PBIO) announced Thursday that in 2019 — for the second year in a row — more than 20 scientific journal articles were published that highlight the benefits of its patented pressure cycling technology (PCT) platform.

"PCT-related scientific papers published in 2019 highlighted new and/or improved applications of the PCT platform in a number of important and exciting areas of research, including cancer, food safety, and proteomics," Global Director of Sales & Marketing Roxana McCloskey said in a statement.

"We are particularly pleased that several publications described protocols for combining the PCT platform with existing technologies from other companies to fill a significant unmet need for high throughput protein processing of cancer biopsy tissues."

READ: Pressure BioSciences sees soaring consumables sales in third quarter, projects revenue growth in 2020

Several publications described the use of the PCT platform to rapidly release molecules for analysis from tissue samples, which can be used to achieve a better understanding of patients' cancers, disease progression and treatment options.

Regarding food, journals highlighted applications using PBI's ultra-high-pressure HUB instrument system for killing food borne bacteria. The company said it believes articles in that vein will increase sales of PCT Systems in the food safety industry.

Additionally, papers reported on the PCT's use in proteomic research, which covers proteins made or modified by an organism. Studies of proteins using PBI's high pressure PCT platform included protein structure, drug delivery, and disease states, the company said.

The goal is to reach routine use of the PCT platform in clinical diagnostics and precision medicine.

"We are pleased that the number of PCT-related publications in 2019 exceeded 20 for the second year in a row," CEO Richard Schumacher said. "We are also pleased with the wide range of applications highlighted in the publications, as these applications fulfill needs in many large and growing markets."


Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 2.25

Market Cap: \$5.4 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: PBIO

Listing: OTCQB

52 week	High	Low
	4.03	0.6006

Sector: Medical technology & services

Website: www.pressurebiosciences.com

Company Synopsis:

Pressure BioSciences Inc. (OTCQB: PBIO): A leader in the sale of innovative, broadly enabling, pressure-based instruments and consumables for the worldwide life sciences industry.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).